Interleukin 21-Armed EGFR-VHH-CAR-T Cell Therapy for the Treatment of Esophageal Squamous Cell Carcinoma

QR Code

Interleukin 21-Armed EGFR-VHH-CAR-T Cell Therapy for the Treatment of Esophageal Squamous Cell Carcinoma

<b>Background/Objectives:</b> Esophageal squamous cell carcinoma (ESCC) is a common form of esophageal cancer with a poor prognosis and limited treatment options. Epidermal growth factor receptor (EGFR), an overexpressed oncogenic gene in all ESCC patients, is an attractive target for de...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chenglin Zhang, Yanyan Liu, Haoran Guo, Ying Peng, Lei Huang, Shuangshuang Lu, Zhimin Wang
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Biomedicines
Subjects:	ESCC EGFR nanobody CAR-T cells human IL-21
Online Access:	https://www.mdpi.com/2227-9059/13/7/1598
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer
by: Lu Xia, et al.
Published: (2025-07-01)

Unraveling the Oncogenic Characteristics of the Cytolinker, Plectin, in Esophageal Squamous Cell CarcinomaSummary
by: Lili Qiao, et al.
Published: (2025-01-01)

Unique Function in Cancer Stemness and Prognostic Significance of <i>EMX2</i> in Esophageal Squamous Cell Carcinoma
by: Shoichi Fumoto, et al.
Published: (2025-06-01)

Overcoming immune resistance in advanced esophageal squamous cell carcinoma with recombinant human adenovirus type 5 by impacting the immune microenvironment: a case report
by: Zhongting Wang, et al.
Published: (2025-06-01)

Impact of seasons on elderly patients with esophageal squamous cell carcinoma following esophagectomy: a propensity score matching analysis
by: Kexun Li, et al.
Published: (2025-06-01)

First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-07-01)

Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI
by: Yiming ZENG, et al.
Published: (2025-06-01)

Neutralization of the Pandemic Influenza A/H1N1 Virus with <i>Lama glama</i> Humanized Nanobodies (VHH)
by: Zeila Yazmín Páez-Hernández, et al.
Published: (2025-05-01)

CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors
by: Yunjia Xian, et al.
Published: (2025-06-01)

A Novel Method for Preparing Uniform Micro-Sized Dry Powder Formulations, Including Aggregation-Controlled VHH
by: Tatsuru Moritani, et al.
Published: (2025-03-01)

Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer
by: O. N. Pavlova, et al.
Published: (2024-04-01)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
by: Lennart Kühl, et al.
Published: (2023-12-01)

Targeting p-FGFR1<sup>Y654</sup> Enhances CD8+ T Cells Infiltration and Overcomes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma by Regulating the CXCL8–CXCR2 Axis
by: Hong Luo, et al.
Published: (2025-07-01)

Computational nanobody design through deep generative modeling and epitope landscape profiling
by: Liyun Huo, et al.
Published: (2025-01-01)

A nanobody-based blocking enzyme-linked immunosorbent assay for detecting antibodies against pseudorabies virus glycoprotein E
by: Huanhuan Lü, et al.
Published: (2024-04-01)

PERBEDAAN FAKTOR RISIKO PENDERITA ADENOKARSINOMA PARU DENGAN MUTASI EGFR DAN NON MUTASI EGFR
by: Felicia Angga Putriani, et al.
Published: (2019-02-01)

Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM
by: Danielle R. Cook, et al.
Published: (2025-07-01)

The Effects of Silibinin Combined With EGFR‐TKIs in the Treatment of NSCLC
by: Xiaocen Wang
Published: (2025-02-01)

Enhancing CAR T‐cell therapy manufacturing efficiency through semi‐automated bioprocessing
by: Jason Isaacson, et al.
Published: (2025-01-01)

MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
by: V. A. Shamanin, et al.
Published: (2018-11-01)

Tracing the development of CAR-T cell design: from concept to next-generation platforms
by: Ahdab A. Alsaieedi, et al.
Published: (2025-07-01)

Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and Challenges
by: Xuexue Zhou, et al.
Published: (2025-05-01)

Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway
by: Liu Huiyang, et al.
Published: (2024-11-01)

EchoBack‐CAR T cells: Tuning immunity with sound
by: Longwei Liu, et al.
Published: (2025-07-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors
by: Fatemah S. Albalawi, et al.
Published: (2025-07-01)

Generative Deep Learning Design of Single-Domain Antibodies Against Venezuelan Equine Encephalitis Virus
by: Jinny L. Liu, et al.
Published: (2025-05-01)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

A Case Report of Coexistence of EGFR and ROS-1 Gene Mutations  in Non-small Cell Lung Cancer
by: Juan ZHAO, et al.
Published: (2025-06-01)

The sports car : its design and performance.
by: Campbell, Colin, 1913-
Published: (1969)

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01)

Structural alterations of the EGFR gene in glioblastoma samples as a prognostic factor and molecular target for therapy
by: V. O. Varachev, et al.
Published: (2024-10-01)

Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression
by: Xiaomin Zhang, et al.
Published: (2025-07-01)

Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells
by: Aida López Ruiz, et al.
Published: (2025-06-01)

Traditional Chinese Medicines as Anticancer Agents for Non-Small Cell Lung Cancer with EGFR Mutations: A Review
by: Wang Z, et al.
Published: (2025-06-01)

NANOBODIES: STRUCTURE, MANUFACTURING, APPLICATION (REVIEW)
by: A. V. Shatalova, et al.
Published: (2019-02-01)

Generation of nanobodies against the F protein of respiratory syncytial virus and establishment of an indirect immunofluorescence assay
by: Qianqian Wang, et al.
Published: (2025-07-01)

Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations
by: Le LT, et al.
Published: (2025-07-01)

Affibody-Modified Gd@C-Dots with Efficient Renal Clearance for Enhanced MRI of EGFR Expression in Non-Small-Cell Lung Cancer [Corrigendum]
by: Wu Y, et al.
Published: (2025-07-01)

Efek Mutasi K-RAS pada Kanker Kolorektal terhadap Terapi Antibodi Monoklonal anti EGFR
by: Farid Sastra Nagara, et al.
Published: (2008-12-01)